It has been well-established that transradial access (TRA) has significant benefit compared to transfemoral arterial access (TFA) for patients at high risk for arterial access bleeding. This advantage is most notable for patients presenting with acute coronary syndromes – especially ST-elevation myocardial infarction [ ]. Other benefits of TRA include early ambulation, shorter hospital stay, lower costs, and a strong patient preference for this method of arterial access [ ]. This has led to significant uptake in TRA globally and more recently in the United States [ ]. As the TRA experience has matured, extensive study has led to a better understanding of the challenges presented and optimization of technique. This issue ofCardiovascular Revascularization Medicine (CRM) contains three manuscripts that pertain to this continued refinement.